Thanks for posting the detailed analysis.  Product sales estimates are roughly in line with what I was figuring.  I said I thought it wouldn't be over $25 Cdn on Monday and it closed at about $24.  Kind of surprised it's down again today, I was figuring about 10 times sales would get it to roughly $23 - $25 Cdn. Might be time to add a bit more if it goes back under $20.  I think the analyst targets are a bit aggressive, especially the ones at $30+ USD but maybe we can get to $30 Cdn by year end if the roll out goes well.  Interesting that they figure covid reduces the market penetration in 2021.  Hopefully the vaccines have largely taken care of that issue by late 2021.  Big thing for AUP is finding another target for the drug.  Right now there is no pipeline.